Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.12447PMID 24962473PMCID PMC4243877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of the Effect of Macitentan on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

  2014cited by this paper
• Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

  2014cited by this paper
• Macitentan Does Not Interfere with Hepatic Bile Salt Transport

  2014cited by this paper
• Macitentan: First Global Approval

  2013cited by this paper
• The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects

  2013cited by this paper
• Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.

  2013cited by this paper
• New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists

  2013cited by this paper
• Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

  2013cited by this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple‐dose study in healthy subjects

  2013cited by this paper
• Macitentan and morbidity and mortality in pulmonary arterial hypertension.

  2013cited by this paper
• Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

  2012cited by this paper
• Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

  2011cited by this paper
• Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.

  2011cited by this paper
• Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa

  2011cited by this paper
• Macitentan: entry-into-humans study with a new endothelin receptor antagonist

  2011cited by this paper
• Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

  2009cited by this paper
• Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study

  2009cited by this paper
• Pulmonary arterial hypertension: an overview of current pharmacologic treatment.

  2008cited by this paper
• Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

  2008cited by this paper
• Review: Therapeutic advances in pulmonary arterial hypertension

  2008cited by this paper
• Pulmonary arterial hypertension and its association with HIV infection: an overview

  2008cited by this paper
• Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

  2008cited by this paper
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

  2007cited by this paper
• Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

  2007cited by this paper
• Combination therapy and new types of agents for pulmonary arterial hypertension.

  2007cited by this paper
• Management of pulmonary arterial hypertension with a focus on combination therapies.

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

  2007cited by this paper
• Management of heart failure with pulmonary hypertension

  2005cited by this paper
• Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

  2005cited by this paper
• Sildenafil citrate therapy for pulmonary arterial hypertension.

  2005cited by this paper
• The efficacy and safety of PDE5 inhibitors.

  2005cited by this paper
• Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination

  2005cited by this paper
• Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.

  2004cited by this paper
• Clinical classification of pulmonary hypertension.

  2004cited by this paper
• Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

  2004cited by this paper
• Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

  2004cited by this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cited by this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cited by this paper
• Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.

  2001cited by this paper
• Contraceptive effectiveness: cytochromes and induction.

  2000cited by this paper
• Pulmonary hypertension related to drugs and toxins.

  1999cited by this paper
• Primary pulmonary hypertension.

  1997cited by this paper
• Human P450 metabolism of warfarin.

  1997cited by this paper
• Primary pulmonary hypertension.

  1987cited by this paper
• Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations

  year unknowncited by this paper

• Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data

  2024cites this paper
• New Psychoactive Substances, New Behaviours, New Drug-drug Interactions: Pharmacology of a Slam Session.

  2023cites this paper
• Возможности и ограничения для начальной комбинированной специфической терапии легочной артериальной гипертензии в Российской Федерации

  2021cites this paper
• Sildenafil 4.0—Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era

  2021cites this paper
• The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern

  2020cites this paper
• Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension

  2020cites this paper
• [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].

  2020cites this paper
• DHPS_A_173050 71..85

  2019cites this paper
• Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience

  2019cites this paper
• Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update

  2019cites this paper
• Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

  2018cites this paper
• Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects

  2017cites this paper
• The Discovery of Macitentan - A Standard Medicinal Chemistry Program?

  2017cites this paper
• Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit®).

  2017cites this paper
• Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment

  2017cites this paper
• Sildenafil in Infants and Children

  2017cites this paper
• OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS

  2017cites this paper
• Plasma sFlt-1 Fluctuations in Response to Pulmonary ArterialHypertension Treatment

  2017cites this paper
• Endothelin Receptor Antagonist

  2017cites this paper
• Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects

  2016cites this paper
• Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions

  2016cites this paper
• Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus

  2015cites this paper
• Development of macitentan for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan

  2015cites this paper
• Diffuse Alveolar Hemorrhage Confirmed by Bronchoalveolar Lavage in a Patient with Hemoptysis after Sildenafil Use for Erectile Dysfunction

  2015cites this paper
• Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension

  2015cites this paper
• Macitentan , a novel ERA : metabolism and drug interactions

  2014cites this paper
• Vascular Health and Risk Management Dovepress Macitentan for the Treatment of Pulmonary Arterial Hypertension the Endothelins and the Endothelin Receptors

  year unknowncites this paper